Friday, March 24, 2017 11:09:51 PM
_____________________________________________________________________
WDR:
Thank you for agreeing to delete the erroneous statement in your article regarding GJG's alleged conversion of their preferred stock for common stock. As you now concede, GJG never did this. The retraction of this very significant, but very wrong, "fact" raises serious questions regarding the veracity of your article.
Unfortunately, the alleged conversion of preferred stock by GJG was not the only error in your article. To the contrary, as noted in my earlier comment, there is no evidence to support ANY of the alleged "facts" in your article.
For example, there is no evidence to suggest that GJG is intending to sell some or all of its stock as you suggest. The fact that GJG has held its stock for years, even when the stock was at $4, belies your supposition that a sale is imminent.
Moreover, it would make no sense for GJG to sell its shares at current levels when it did not sell any shares when the price was $4.00. In addition, if GJG were to now dump its shares, and further depress the stock price, it would hurt its investment in this company.
If you speak with GJG, you will likely become convinced it is in this investment for the long haul, that will only terminate when Matinas is bought out by a pharmaceutical company having an interest in its patented encochleation technology.
Nor is there any evidence that supports your erroneous contention that Rutgers ran a failed clinical trial on any of the drugs sold to Matinas.
I challenge you to present any evidence in support of this claim. You will be unable to find such evidence as there were no such trials.
If you have any evidence which supports these, or any of the other "facts" I refuted in my earlier comment, I would ask that you provide such evidence in a responsive comment, or supplemental article.
If you have no evidence to support the alleged facts upon which your article is based, I would respectfully suggest you retract it.
It is one thing to publish an article without any support for the alleged facts upon which the article is based.
It is quite another thing to refuse to retract the article when shown that the facts are wrong.
Please govern yourself accordingly.
LM
Recent MTNB News
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Matinas BioPharma Prices $10 Million Registered Direct Offering • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/27/2024 08:05:00 PM
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response • GlobeNewswire Inc. • 03/22/2024 01:15:00 PM
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 03/22/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:05:14 PM
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 12:35:32 PM
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 12:30:25 PM
- Matinas BioPharma to Present at Biotech Showcase 2024 • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 12:40:40 PM
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides • GlobeNewswire Inc. • 12/27/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 12:40:46 PM
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA • GlobeNewswire Inc. • 12/21/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:29 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM